1. Autophagy
  2. Autophagy

Autophagy

Autophagy is a lysosome-dependent degradative process that protects cancer cells from multiple stresses.

Autophagy, the sequestration of organelles and proteins in autophagic vesicles (AVs) and degradation of this cargo through lysosomal fusion, allows tumor cells to survive metabolic and therapeutic stresses. Therapy-induced autophagy is a key resistance mechanism to many anticancer agents, and autophagy levels are increased in most cancers. Chloroquine derivatives block autophagy by impairing lysosomal function.

Autophagy plays an emerging role in immune responses against intracellular pathogens and regulates distinct immunologic processes, important for the initiation of potent innate or adaptive immune responses.

Autophagy is important for the transport of cytoplasmic constituents such as damaged mitochondria and protein aggregates to lysosomes where they are degraded and recycled back into the cytoplasm.

Autophagy Related Products (518):

Cat. No. Product Name Effect Purity
  • HY-11109
    TAK-242 Inhibitor 99.95%
    TAK-242 is a novel small molecule TLR4 signaling inhibitor, selectively inhibits the TLR4-mediated production of cytokines and NO.
  • HY-12320
    Cycloheximide Inhibitor 99.17%
    Cycloheximide is an inhibitor of protein biosynthesis in eukaryotic organisms, with IC50 of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively.
  • HY-70002
    Enzalutamide Activator 99.52%
    Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells.
  • HY-10108
    LY294002 Inhibitor 99.97%
    LY294002 is a broad-spectrum inhibitor of PI3K, with IC50 of 0.5/0.57/0.97 μM for PI3Kα/δ/β, respectively, also potently inhibits CK2 with IC50 of 98 nM.
  • HY-13030
    (+)-JQ-1 Activator 99.86%
    (+)-JQ-1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for the first and second bromodomain (BRD4(1/2)).
  • HY-12855A
    Lys01 trihydrochloride Inhibitor
    Lys01 trihydrochloride (Lys05) is a novel lysosomal autophagy inhibitor with IC50 values of 3.6, 3.8, 6 and 7.9 μM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay.
  • HY-12794
    Vps34-PIK-III Inhibitor
    Vps34-PIK-III is a potent and selective inhibitor of VPS34 with an IC50 of 18 nM.
  • HY-N2113
    Glaucocalyxin B Activator
    Glaucocalyxin B is an ent kaurane diterpenoid isolated from the Chinese traditional medicine Rabdosia japonica with anticancer and antitumor activity; decreases the growth of HL-60 cells with an IC50 of approximately 5.86 μM at 24 h.
  • HY-10256
    SB 203580 Activator 99.54%
    SB 203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM, also blocks PKB phosphorylation with IC50 of 3-5 μM.
  • HY-12041
    SP600125 Inhibitor 98.87%
    SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM, respectively.
  • HY-10162
    Olaparib Activator 99.65%
    Olaparib is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP-1 and PARP-2, respectively.
  • HY-12031
    U0126 Inhibitor 98.03%
    U0126 is a non-ATP competitive MEK inhibitor, with IC50 of 70 nM and 60 nM for MEK1 and MEK2, respectively.
  • HY-15142
    Doxorubicin hydrochloride Activator 99.63%
    Doxorubicin hydrochloride is a Topoisomerase II (Top2) catalytic inhibitor, also is a broad spectrum antibiotic used in the treatment of cancers, with IC50 of 374 nM for Hela cells.
  • HY-17559
    Actinomycin D Activator 99.89%
    Actinomycin D inhibits DNA repair with IC50 of 0.42 μM.
  • HY-19312
    3-Methyladenine Inhibitor 99.84%
    3-Methyladenine is a selective PI3K inhibitor with IC50 of 25 μM and 60 μM for Vps34 and PI3Kγ, respectively, and it can inhibit all PtdIns3Ks at 10 mM.
  • HY-10227
    Bortezomib Modulator 99.72%
    Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM.
  • HY-13418
    Dorsomorphin dihydrochloride Inhibitor 99.73%
    Dorsomorphin dihydrochloride is a potent and selective AMPK inhibitor, that is competitive with ATP, with Ki of 109±16 nM in the absence of AMP.
  • HY-13316
    Mitomycin C Activator 99.45%
    Mitomycin C is a DNA-damaging agent and small-molecule inhibitor effectively sensitize cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
  • HY-10181
    Dasatinib Activator 99.84%
    Dasatinib is a potent and dual AblWT/Src inhibitor IC50 of 0.6 nM/0.8 nM respectively; also inhibits c-KitWT/c-KitD816V with IC50 of 79 nM/37 nM.
  • HY-13027
    DAPT Activator 99.25%
    DAPT is a γ-secretase inhibitor, reduces the total beta-amyloid peptide () production with IC50 of 20 nM in HEK 293 cells.